Reinfusion of concentrated ascitic fluid versus total paracentesis: A randomized prospective trial

Agnese Graziotto, Lorenzo Rossaro, Paolo Inturri, Mario Salvagnini

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We compared the efficacy and safety of apheresis and reinfusion of concentrated ascites (ARCA) versus total paracentesis plus intravenous albumin (PARA) in a prospective trial on cirrhotic patients with tense ascites. Twenty-four patients were randomized to either ARCA (N = 12) or PARA (N = 12), and followed for two years. Sex, age, child's class, and renal and liver function were similar in the two groups. The times of the procedures were 2.7 ± 1.0 (ARCA) vs 2.2 ± 1.1 (PARA) hr, with removal of 8.8 ± 3.5 (ARCA) and 6.9 ± 3.4 (PARA) liters of ascites and intravenous infusion of 59.8 ± 35.2 (ARCA) and 42.5 ± 20.5 (PARA) g of albumin. Both procedures were safe. Biochemical signs of coagulative disturbances having no clinical relevance were observed after ARCA, with an increase in prothrombin time (P = 0.005) and serum FSP (P = 0.02). No significant changes in renal function, serum albumin, or plasma and urinary electrolytes were shown. Plasma renin activity increased after PARA (P = 0.02) and plasma atrial natriuretic factor increased after ARCA (P = 0.008), although no differences were observed in diuresis in the immediate follow-up. During the long-term follow-up, patient survival and recurrence of tense ascites were the same in both groups. We conclude that apheresis and reinfusion of concentrated ascites are as safe and effective as total paracentesis with albumin infusion for the treatment of tense ascites in cirrhotic patients.

Original languageEnglish (US)
Pages (from-to)1708-1714
Number of pages7
JournalDigestive Diseases and Sciences
Volume42
Issue number8
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Paracentesis
Ascitic Fluid
Ascites
Blood Component Removal
Albumins
Kidney
Diuresis
Prothrombin Time
Atrial Natriuretic Factor
Renin
Intravenous Infusions
Serum Albumin
Electrolytes

Keywords

  • Albumin
  • Concentrated ascites reinfusion
  • Liver cirrhosis
  • Paracentesis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Reinfusion of concentrated ascitic fluid versus total paracentesis : A randomized prospective trial. / Graziotto, Agnese; Rossaro, Lorenzo; Inturri, Paolo; Salvagnini, Mario.

In: Digestive Diseases and Sciences, Vol. 42, No. 8, 1997, p. 1708-1714.

Research output: Contribution to journalArticle

Graziotto, Agnese ; Rossaro, Lorenzo ; Inturri, Paolo ; Salvagnini, Mario. / Reinfusion of concentrated ascitic fluid versus total paracentesis : A randomized prospective trial. In: Digestive Diseases and Sciences. 1997 ; Vol. 42, No. 8. pp. 1708-1714.
@article{1994dfd92e3a4d09af904cf9ef75f473,
title = "Reinfusion of concentrated ascitic fluid versus total paracentesis: A randomized prospective trial",
abstract = "We compared the efficacy and safety of apheresis and reinfusion of concentrated ascites (ARCA) versus total paracentesis plus intravenous albumin (PARA) in a prospective trial on cirrhotic patients with tense ascites. Twenty-four patients were randomized to either ARCA (N = 12) or PARA (N = 12), and followed for two years. Sex, age, child's class, and renal and liver function were similar in the two groups. The times of the procedures were 2.7 ± 1.0 (ARCA) vs 2.2 ± 1.1 (PARA) hr, with removal of 8.8 ± 3.5 (ARCA) and 6.9 ± 3.4 (PARA) liters of ascites and intravenous infusion of 59.8 ± 35.2 (ARCA) and 42.5 ± 20.5 (PARA) g of albumin. Both procedures were safe. Biochemical signs of coagulative disturbances having no clinical relevance were observed after ARCA, with an increase in prothrombin time (P = 0.005) and serum FSP (P = 0.02). No significant changes in renal function, serum albumin, or plasma and urinary electrolytes were shown. Plasma renin activity increased after PARA (P = 0.02) and plasma atrial natriuretic factor increased after ARCA (P = 0.008), although no differences were observed in diuresis in the immediate follow-up. During the long-term follow-up, patient survival and recurrence of tense ascites were the same in both groups. We conclude that apheresis and reinfusion of concentrated ascites are as safe and effective as total paracentesis with albumin infusion for the treatment of tense ascites in cirrhotic patients.",
keywords = "Albumin, Concentrated ascites reinfusion, Liver cirrhosis, Paracentesis",
author = "Agnese Graziotto and Lorenzo Rossaro and Paolo Inturri and Mario Salvagnini",
year = "1997",
doi = "10.1023/A:1018865516168",
language = "English (US)",
volume = "42",
pages = "1708--1714",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Reinfusion of concentrated ascitic fluid versus total paracentesis

T2 - A randomized prospective trial

AU - Graziotto, Agnese

AU - Rossaro, Lorenzo

AU - Inturri, Paolo

AU - Salvagnini, Mario

PY - 1997

Y1 - 1997

N2 - We compared the efficacy and safety of apheresis and reinfusion of concentrated ascites (ARCA) versus total paracentesis plus intravenous albumin (PARA) in a prospective trial on cirrhotic patients with tense ascites. Twenty-four patients were randomized to either ARCA (N = 12) or PARA (N = 12), and followed for two years. Sex, age, child's class, and renal and liver function were similar in the two groups. The times of the procedures were 2.7 ± 1.0 (ARCA) vs 2.2 ± 1.1 (PARA) hr, with removal of 8.8 ± 3.5 (ARCA) and 6.9 ± 3.4 (PARA) liters of ascites and intravenous infusion of 59.8 ± 35.2 (ARCA) and 42.5 ± 20.5 (PARA) g of albumin. Both procedures were safe. Biochemical signs of coagulative disturbances having no clinical relevance were observed after ARCA, with an increase in prothrombin time (P = 0.005) and serum FSP (P = 0.02). No significant changes in renal function, serum albumin, or plasma and urinary electrolytes were shown. Plasma renin activity increased after PARA (P = 0.02) and plasma atrial natriuretic factor increased after ARCA (P = 0.008), although no differences were observed in diuresis in the immediate follow-up. During the long-term follow-up, patient survival and recurrence of tense ascites were the same in both groups. We conclude that apheresis and reinfusion of concentrated ascites are as safe and effective as total paracentesis with albumin infusion for the treatment of tense ascites in cirrhotic patients.

AB - We compared the efficacy and safety of apheresis and reinfusion of concentrated ascites (ARCA) versus total paracentesis plus intravenous albumin (PARA) in a prospective trial on cirrhotic patients with tense ascites. Twenty-four patients were randomized to either ARCA (N = 12) or PARA (N = 12), and followed for two years. Sex, age, child's class, and renal and liver function were similar in the two groups. The times of the procedures were 2.7 ± 1.0 (ARCA) vs 2.2 ± 1.1 (PARA) hr, with removal of 8.8 ± 3.5 (ARCA) and 6.9 ± 3.4 (PARA) liters of ascites and intravenous infusion of 59.8 ± 35.2 (ARCA) and 42.5 ± 20.5 (PARA) g of albumin. Both procedures were safe. Biochemical signs of coagulative disturbances having no clinical relevance were observed after ARCA, with an increase in prothrombin time (P = 0.005) and serum FSP (P = 0.02). No significant changes in renal function, serum albumin, or plasma and urinary electrolytes were shown. Plasma renin activity increased after PARA (P = 0.02) and plasma atrial natriuretic factor increased after ARCA (P = 0.008), although no differences were observed in diuresis in the immediate follow-up. During the long-term follow-up, patient survival and recurrence of tense ascites were the same in both groups. We conclude that apheresis and reinfusion of concentrated ascites are as safe and effective as total paracentesis with albumin infusion for the treatment of tense ascites in cirrhotic patients.

KW - Albumin

KW - Concentrated ascites reinfusion

KW - Liver cirrhosis

KW - Paracentesis

UR - http://www.scopus.com/inward/record.url?scp=0030881630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030881630&partnerID=8YFLogxK

U2 - 10.1023/A:1018865516168

DO - 10.1023/A:1018865516168

M3 - Article

C2 - 9286238

AN - SCOPUS:0030881630

VL - 42

SP - 1708

EP - 1714

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 8

ER -